Korean J Intern Med > Volume 35(2); 2020 > Article |
|
Characteristic | PE without cancer (n = 273) | PE with cancer (n = 703) | Total (n = 976) | p value |
---|---|---|---|---|
Initial symptom/sign | ||||
No symptom | 36 (13.2) | 383 (54.5) | 419 (42.9) | < 0.001 |
Dyspnea | 139 (50.9) | 201 (28.6) | 340 (34.8) | < 0.001 |
Chest pain | 41 (15.0) | 32 (4.6) | 73 (7.5) | < 0.001 |
Leg swelling | 47 (17.2) | 65 (9.2) | 112 (11.5) | < 0.001 |
Fever | 50 (18.3) | 40 (5.7) | 90 (9.2) | < 0.001 |
Hypoxia | 134 (50.0) | 151 (22.3) | 285 (30.2) | < 0.001 |
Tachycardia | 114 (42.5) | 233 (34.4) | 347 (36.7) | 0.020 |
Shock | 35 (13.1) | 36 (5.3) | 71 (7.5) | < 0.001 |
Unexpected PEa | 40 (14.7) | 474 (67.4) | 514 (52.7) | < 0.001 |
Laboratory finding | ||||
D-dimer | 5.9 (2.8–15.4) | 9.5 (4.7–19.1) | 8.0 (3.7–18.0) | < 0.001 |
Hemoglobin | 12.1 (10.0–13.4) | 11.2 (10.1–12.6) | 11.4 (10.0–13.0) | 0.001 |
Platelet | 197 (152–250) | 203 (141–270) | 200 (144–264) | 0.751 |
NT-proBNP | 900 (144–3,625) | 436 (183–1,630) | 586 (167–2,502) | 0.028 |
CK-MB | 1.97 (0.78–4.75) | 1.56 (0.57–3.32) | 1.83 (0.69–3.91) | 0.024 |
Troponin I | 0.029 (0.006–0.132) | 0.019(0.006–0.115) | 0.022 (0.006–0.118) | 0.145 |
Echocardiographic finding | ||||
RV dysfunction | 41 (27.2) | 17 (10.3) | 58 (18.4) | < 0.001 |
D-shaped LV | 32 (21.2) | 14 (8.5) | 46 (14.6) | 0.001 |
CT finding | ||||
Proximalb | 170 (62.3) | 415 (59.0) | 585 (59.9) | 0.354 |
Bilateral involvement | 140 (51.3) | 301 (42.8) | 441 (45.2) | 0.017 |
Lung infarction | 28 (10.3) | 37 (5.3) | 65 (6.7) | 0.005 |
Coexisting DVTc | 139 (60.2) | 160 (57.6) | 299 (58.7) | 0.550 |
Distal DVT | 45 (19.5) | 52 (18.7) | 97 (19.1) | 0.836 |
Proximal DVT | 94 (40.7) | 108 (38.8) | 202 (39.7) | 0.836 |
Values are presented as number (%) or median (interquartile range).
PE, pulmonary embolism; NT-proBNP, N-terminal pro-blood natriuretic peptide; CK-MB, creatine kinase myocardial band; RV, right ventricle; LV, left ventricle; CT, computed tomography; DVT, deep vein thrombosis.
Characteristic | PE without cancer (n = 273) | PE with cancer (n = 703) | Total (n = 976) | p value |
---|---|---|---|---|
PE treatment | 223 (81.7) | 436 (62.0) | 659 (67.5) | < 0.001 |
Anticoagulation | ||||
VKA | 184 (67.4) | 268 (38.1) | 452 (46.3) | |
LMWH | 18 (6.6) | 156 (22.2) | 174 (17.8) | |
NOAC | 21 (7.7) | 12 (1.7) | 33 (3.4) | |
Thrombolysisa | 22 (8.1) | 6 (0.9) | 28 (2.9) | < 0.001 |
Thrombectomya | 7 (2.6) | 5 (0.7) | 12 (1.2) | 0.045 |
Anticoagulation duration, mon | 6.0 (3.2–11.9) | 4.3 (2.3–7.0) | 5.0 (2.6–7.8) | 0.017 |
Mean follow-up duration, mon | 17.5 (3.0–40.2) | 8.9 (2.6–23.8) | 10.4 (2.6–28.5) | < 0.001 |
Adjusted for age, gender, body mass index, no anticoagulation, duration of treatment, proximal located PE, bilateral lung involvement, shock, tachycardia, smoking, right ventricular dysfunction, and unexpected PE.
VTE, venous thromboembolism; PE, pulmonary embolism; HR, hazard ratio; CI, confidence interval.